Clinical pathological characteristics and prognosis of 468 thymoma patients
- VernacularTitle:468 例胸腺瘤患者的临床病理特征及预后的回顾性队列研究
- Author:
Yulong TAN
1
;
An WANG
1
;
Zhouyi LU
1
;
Dong XU
1
;
Xuan WANG
1
;
Zhenhua HAO
1
;
Meng SHI
1
;
Dayu HUANG
1
;
Huijun ZHANG
1
;
Shaohua WANG
1
;
Qinyun MA
1
;
Xiaofeng CHEN
1
Author Information
1. Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, Shanghai, 200041, P.R.China
- Publication Type:Journal Article
- Keywords:
Thymoma;
WHO pathological classification;
Masaoka stage;
myasthenia gravis;
prognosis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(12):1427-1431
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the correlation of WHO pathological classification and Masaoka stage of thymomas with its prognosis. Methods A total of 468 patients with thymomas who received surgeries during 2009-2019 in Huashan Hospital, Fudan University, were collected. There were 234 males and 234 females with an average age of 21-83 (49.6±18.7) years. A total of 132 patients underwent video-assisted thoracic surgery (VATS) and 336 patients underwent thymectomy with median sternal incision. The follow-up time was 5.7±2.8 years. The clinical data of the patients were analyzed. Results The amount of intraoperative bleeding was 178.3±133.5 mL in the median sternal incision group, and 164.8±184.1 mL in the VATS group (P=0.537). The operative time was 3.3±0.7 h in the median sternal incision group and 3.4±1.2 h in the VATS group (P=0.376). Postoperative active bleeding, phrenic nerve injury and chylothorax complications occurred in 8 patients, 9 patients and 1 patient in the VATS group, respectively, and 37 patients, 31 patients and 7 patients in the median sternal incision group, respectively. There was no statistical difference between the two groups (P=0.102, 0.402, 0.320). The 5-year cumulative progression free survival (PFS) rates of patients with WHO type A, AB, B1, B2, B3 and C thymomas were 100.0%, 100.0%, 95.7%, 81.4%, 67.5% and 50.0%, respectively (P<0.001). The 5-year PFS rates of patients with Masaoka stageⅠ-Ⅳ thymomas were 96.1%, 89.2%, 68.6% and 19.3%, respectively (P<0.001). The 5-year PFS rate was 87.3% in patients with myasthenia gravis (MG) and 78.2% in patients without MG (P<0.001). The 5-year PFS rates of patients with different surgeries were 82.4% and 83.8%, respectively (P=0.904). Conclusion WHO pathological classification and Masaoka stage have significant clinical prognosis suggestive effect. Thymoma patients combined with MG have better prognosis, which suggests early diagnosis and treatment of thymoma are important.
